MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jhep.2018.09.029

Медицинская библиотека · Journal of hepatology · 2018

Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy.

Nishibatake Kinoshita Mizuki, Minami Tatsuya, Tateishi Ryosuke, Wake Taijiro, Nakagomi Ryo, Fujiwara Naoto, Sato Masaya, Uchino Koji, Enooku Kenichiro, Nakagawa Hayato, Asaoka Yoshinari, Shiina Shuichiro, Koike Kazuhiko

Сравнительное исследованиеСтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND & AIMS: It remains controversial whether direct-acting antivirals (DAAs) accelerate the recurrence of hepatitis C-related hepatocellular carcinoma (HCC) after curative therapy. This study aimed to evaluate HCC recurrence after DAA treatment of chronic hepatitis C.

METHODS

We enrolled patients with a history of successful radiofrequency ablation treatment for hepatitis C-related HCC who received antiviral therapy with DAAs (DAA group: 147 patients) or with interferon (IFN)-based therapy (IFN group: 156 patients). We assessed HCC recurrence rates from the initiation of antiviral therapy using the Kaplan-Meier method and evaluated risk factors for HCC recurrence by multivariate Cox proportional hazard regression analysis. The recurrence pattern was categorized as follows: intrahepatic recurrence with a single tumor <2 cm (stage 0), a single tumor or up to 3 tumors ≤3 cm (stage A), multinodular (stage B), and extrahepatic metastasis or macrovascular invasion (stage C).

RESULTS

The recurrence rates at 1 and 2 years were 39% and 61% in the IFN group and 39% and 60% in the DAA group, respectively (p = 0.43). Multivariate analysis identified higher lens culinaris agglutinin-reactive fraction of alpha-fetoprotein level, a history of multiple HCC treatments, and a shorter interval between HCC treatment and initiation of antiviral therapy as independent risk factors for HCC recurrence. HCC recurrence in stage 0, A, B, and C was found in 56 (41%), 60 (44%), 19 (14%), and 1 (0.7%) patients in the IFN group and 35 (44%), 32 (40%), 11 (14%), and 2 (2.5%) patients in the DAA group, respectively (p = 0.70).

CONCLUSIONS

HCC recurrence rates and patterns after initiation of antiviral therapy did not differ between patients who received IFN-based therapy and DAA therapy.

LAY SUMMARY: We detected no significant difference in early hepatocellular carcinoma (HCC) recurrence rates and patterns between patients who received interferon-based and direct-acting antiviral therapy after HCC treatment. High lens culinaris agglutinin-reactive fraction of alpha-fetoprotein level, short recurrence-free period, and a history of multiple HCC treatments were independent risk factors for early HCC recurrence after the initiation of antiviral therapy.

Для цитирования: Nishibatake Kinoshita Mizuki, Minami Tatsuya, Tateishi Ryosuke, Wake Taijiro, Nakagomi Ryo, Fujiwara Naoto, Sato Masaya, Uchino Koji, Enooku Kenichiro, Nakagawa Hayato, Asaoka Yoshinari, Shiina Shuichiro, Koike Kazuhiko. Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy.. Journal of hepatology. 2018. DOI: 10.1016/j.jhep.2018.09.029.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.